Evidence map›Paper›PMID 40782673›Full record

ReviewMed (New York, N.Y.)2025

Alzheimer's disease: Clinical trials to watch.

Marwan Noel Sabbagh, Jessica Kennedy, Jad Majeed, Boris Decourt

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Med (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marwan Noel SabbaghAlzheimer's and Memory Disorders Division, Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA. Electronic address: neuropub@barrowneuro.org.
Jessica KennedyDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Jad MajeedUndergraduate Program, University of Arizona, Tucson, AZ, USA.
Boris DecourtDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsR01AG059008 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI DECOURT, BORIS, SABBAGH, MARWAN NOEL · 2018 to 2023
$3.6M
Repurposing Siponimod for Alzheimer's DiseaseR01AG073212 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI Boris Decourt, MARWAN Noel SABBAGH · 2021 to 2026
$2.8M
NIA NIH HHS P30 AG019610NIA NIH HHS R01 AG059008NIA NIH HHS R01 AG073212
6 · The paper itself

Abstract

Second-generation anti-amyloid therapies (ATTs) offer new options for early Alzheimer's disease treatment, but with modest efficacy and documented adverse events. Here we highlight several ongoing clinical trials, aiming to develop therapeutic agents with higher efficacy and better safety profiles including third-generation ATTs, aggregation inhibitors, Sigma-1 receptor agonists, anti-tau antisense oligonucleotides, and GLP-1 receptor agonists.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesClinical Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsHumansOligonucleotides, Antisensetau ProteinsAmyloid beta-PeptidesGlucagon-Like Peptide-1 Receptor AgonistsOligonucleotides, Antisensetau Proteins

Identifiers

PMID40782673
PMCPMC13290110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.